Key Takeaways
- Tectonic Therapeutic appoints François Nader, M.D., MBA, as independent director and Chair of the Board effective April 1, 2026.
- Nader brings over 30 years of experience in biotechnology leadership, including his current role at Moderna.
- Terry McGuire will resign as Chair but remain on the Board until Tectonic’s 2026 Annual Meeting in June.
Leadership Transition at Tectonic Therapeutic
Tectonic Therapeutic, Inc. has announced the appointment of François Nader, M.D., MBA, as an independent director and Chair of the Board, effective April 1, 2026. Nader joins the clinical-stage biotechnology company known for developing therapeutic proteins and antibodies that modulate G-protein coupled receptors (GPCRs).
With over 30 years of leadership experience in the biotechnology and pharmaceutical sectors, Nader currently serves as an Independent Director at Moderna, where he chairs the Talent & Compensation Committee and the Nominating & Governance Committee. He has also held various leadership positions in several biotechnology companies, guiding significant strategic transactions.
As part of this Board transition, current Chair Terry McGuire will resign from his chair position but will remain a Board member until Tectonic’s upcoming Annual Meeting of Stockholders, expected in June 2026. McGuire expressed his confidence in Nader’s capabilities, stating it has been an honor to serve as Chair and facilitating the company’s growth in GPCR-targeted therapies.
Alise Reicin, M.D., President and CEO of Tectonic Therapeutic, welcomed Nader to the team, highlighting his exceptional leadership, corporate governance expertise, and a strong track record in biotechnology. Nader expressed his enthusiasm for the role, emphasizing the potential for Tectonic’s innovative approach to GPCR biology to advance therapeutic solutions.
Dr. Nader’s extensive background includes leading NPS Pharmaceuticals in transforming it into a leader in rare diseases and senior roles at Aventis. He holds a French Doctorate in Medicine from St. Joseph University in Lebanon and an Executive MBA from the University of Tennessee.
Tectonic Therapeutic focuses on developing biologic medicines aimed at addressing unmet medical needs where existing therapies are limited or absent. The company operates from Watertown, Massachusetts, leveraging its GEODe™ technology to enhance the efficiency of GPCR-targeted drug discovery.
This leadership change is expected to advance Tectonic’s goals of creating shareholder value while pushing its innovative pipeline forward.
The content above is a summary. For more details, see the source article.